Compare Aurora Cannabis Inc (ACB) vs Ecolab Inc. (ECL) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

ECL trades at $283.08, down 0.1% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 EPS of $1.70, meeting expectations, and maintains strong profitability with a net income margin of 12.8%. Recent acquisition of CoolIT for $4.75B enhances its AI cooling portfolio, positioning for long-term growth. Cash flow from operations remains robust at $3.0B in 2025, though net cash flow turned negative due to significant investing activities.

Outlook is positive with 73% analyst buy ratings and a consensus price target of $326.17, implying 15% upside. Risks include rising costs and integration challenges from acquisitions. The stock's high P/E of 38.39 suggests premium valuation, requiring sustained earnings growth to justify current levels.